Tuesday, July 8, 2025
17.5 C
London
HomeFinTechInvex Therapeutics: Receives green light for IIH trial in NZ

Invex Therapeutics: Receives green light for IIH trial in NZ

Date:

Mastercard and Pay4You Unite for Enhanced Spend Management Solutions

A Game-Changing Partnership to Transform Financial Oversight for BusinessesHighlights:...

EPC Urges Directory Service Providers to Collaborate on VOP Scheme

Enhancing the Future of Payments: A Call for Collaboration...

Five More Belgian Banks Join the European Payments Initiative

Enhancing Collaboration in the Payment Landscape Across EuropeHighlights: Five...

Invex Therapeutics Receives green light for IIH trial in NZ

  • Invex Therapeutics (IXC) will commence its IIH EVOLVE Phase III clinical trial after receiving the relevant approvals
  • The company got the green light by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) as well as ethics approval to start the trial
  • The EVOLVE trial will include 240 patients with idiopathic intracranial hypertension to determine the efficacy and safety of Presendin versus placebo over six months
  • The primary endpoint of the trial is to see a change in intracranial pressure as measured by lumbar puncture, both at baseline and at the end of the trial
  • Shares in Invex are down 9.24 per cent, trading at 54 cents at market close.

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories